business

Talphera Seeks FDA Approval to Close NEPHRO CRRT Trial Early

Summarized from Earnings

Talphera has submitted a briefing document to the FDA requesting an early close of its NEPHRO CRRT study enrollment after surpassing 80% statistical power.

Talphera Seeks FDA Approval to Close NEPHRO CRRT Trial Early

Talphera Inc. has submitted a briefing document to the U.S. Food and Drug Administration requesting a Sprint Meeting to discuss closing enrollment in its pivotal NEPHRO CRRT clinical study, based on the number of patients enrolled as of December 31, 2026, the company disclosed in its third-quarter 2026 financial results and business update.

The move signals a potentially significant milestone for the drug developer. The company said its NEPHRO study has exceeded 80% statistical power for the primary endpoint, a threshold that can support a request to close a trial earlier than originally planned without undermining the scientific validity of the results.

Read more NICB Flags Top Insurance Fraud Trends to Watch in 2026 →

Sprint Meetings are a formal FDA mechanism that allows sponsors to seek rapid, targeted guidance on specific development questions. By requesting this type of meeting, Talphera is signaling confidence in the strength of the data accumulated to date and looking to accelerate the trial's path toward a potential regulatory submission.

An early close of enrollment, if granted, would reduce the time and cost associated with completing the pivotal study, potentially bringing the company closer to a New Drug Application filing. Investors and analysts tracking rare-disease and critical-care drug development will likely watch the FDA's response to the Sprint Meeting request as a key near-term catalyst for the company.

Continue reading at Earnings for the full third-quarter financial results and additional business update details.

Frequently Asked Questions

Q.Why is Talphera requesting an early close of the NEPHRO CRRT study?

Talphera says the pivotal NEPHRO study has exceeded 80% statistical power for its primary endpoint, which can support an early close of enrollment without compromising the scientific integrity of the trial.

Q.What is an FDA Sprint Meeting?

A Sprint Meeting is a formal FDA mechanism that allows drug sponsors to seek rapid, targeted guidance on specific development questions, helping to accelerate decision-making during the clinical development process.

Q.When was the NEPHRO CRRT enrollment cutoff date Talphera proposed to the FDA?

Talphera proposed closing enrollment based on the number of patients enrolled as of December 31, 2026, according to the briefing document submitted to the FDA.

More in business →